Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 5/20 | 0.74 |
| ▸ | AR | P10275 | 3/20 | 0.51 |
| ▸ | VNN1 | O95497 | 1/20 | 0.44 |
| ▸ | CCNK | O75909 | 1/20 | 0.41 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.36 |
| ▸ | MTOR | P42345 | 3/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3428095 | 0.87 | F10 (0.83) | F10ARCCNKCDK12 | |
| SCHEMBL3426270 | 0.87 | F10 (0.83) | F10ARVNN1CCNKCDK12 | |
| SCHEMBL3423974 | 0.87 | F10 (0.77) | F10ARVNN1CCNKCDK12 | |
| SCHEMBL3428490 | 0.86 | F10 (0.81) | F10ARVNN1CCNKCDK12 | |
| SCHEMBL3426014 | 0.86 | F10 (0.81) | F10ARCCNKCDK12 | |
| SCHEMBL3423972 | 0.86 | F10 (0.80) | F10ARCCNKCDK12 | |
| SCHEMBL3426538 | 0.85 | F10 (0.86) | F10AR | |
| SCHEMBL3427505 | 0.85 | F10 (1.00) | F10ARHTT | |
| SCHEMBL3428826 | 0.85 | F10 (0.79) | F10ARCCNKCDK12RORC | |
| SCHEMBL3425876 | 0.85 | F10 (0.79) | F10ARCCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732466-B2 | Substituted thiophene carboxamides, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-08 | — | — | US | disclosed |
| US-7732466-B2 | Substituted thiophene carboxamides, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-08 | — | — | US | disclosed |
| US-7732466-B2 | Substituted thiophene carboxamides, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-08 | — | — | US | disclosed |
| US-20060293300-A1 | New substituted thiophene carboxamides, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293300-A1 | New substituted thiophene carboxamides, process for their preparation and their use as medicaments | OTC, TPMT, ABCG2 | F10 1901/4885AR 3491/4885VNN1 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.